Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shereen Abdel Alem, Aisha Elsharkawy, Wafaa El Akel, Ashraf O Abdelaziz, Rabab Maamoun Salama, Manal Hamdy El-Sayed, Mohamed El Kassas, Mahmoud Anees, Mahmoud Shedeed, Fatma Abdelsalam, Dina H Ziada, Yehia El Shazly, Magdy El-Serafy, Imam Waked, Gamal Esmat & Wahid Doss. (2019) Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Review of Gastroenterology & Hepatology 13:10, pages 1009-1016.
Read now
Read now
Juan Pablo Trivella, Julio Gutierrez & Paul Martin. (2015) Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy 16:4, pages 617-624.
Read now
Read now
Articles from other publishers (31)
Sayed Ahmed, Essam Hassan, Ahmed Gomaa, Gamal Esamat, Ahmed Ramadan, Manar Ahmed, Aya Elsayed & Engy A. Wahsh. (2023) Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir
Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients
Infected with HCV Genotype 4. Current Drug Safety 18:2, pages 207-213.
Crossref
Crossref
Saeed M. El-Nahaas, Normeen Hany Rady, Shimaa Malek & Khaled Serag. (2021) Changes in serum interferon-γ-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents. European Journal of Gastroenterology & Hepatology 33:1S, pages e335-e340.
Crossref
Crossref
Claudia Monica Danilescu, Daniela Larisa Sandulescu, Mihail Cristian Pirlog, Costin Teodor Streba & Ion Rogoveanu. (2021) Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy. Diagnostics 11:12, pages 2237.
Crossref
Crossref
Mohamed Mohei El Badry, Doaa Abdelhady Ali, Noha Hamdy Eltaweel & Marwa A. Abdel-Wahed. (2020) Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control. Egyptian Liver Journal 10:1.
Crossref
Crossref
Xue-yan Zheng, Xiao-jun Xu, Yi-yang Liu, Yan-jun Xu, Si-xing Pan, Xin-ying Zeng, Qian Yi, Ni Xiao & Li-feng Lin. (2020) Age-standardized mortality, disability-adjusted life-years and healthy life expectancy in different cultural regions of Guangdong, China: a population-based study of 2005–2015. BMC Public Health 20:1.
Crossref
Crossref
Kamolyut Lapumnuaypol, David Pisarcik, Prapaipan Putthapiban, Weera Sukhumthammarat, Karn Wijarnpreecha, Charat Thongprayoon & Patompong Ungprasert. (2020) Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian Journal of Medical Research 152:6, pages 562.
Crossref
Crossref
Saeed M. El-Nahaas, Rabab Fouad, Aisha Elsharkawy, Marwa Khairy, Walied Elhossary, Ismail Anwar, Zeinab Abdellatif, Rabab M. Maher, Nader Bekheet & Gamal Esmat. (2018) High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. European Journal of Gastroenterology & Hepatology 30:10, pages 1194-1199.
Crossref
Crossref
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han & Jun Yong Park. (2018) Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. Gut and Liver 12:3, pages 324-330.
Crossref
Crossref
Naglaa F. A. Youssef, Mohamed El Kassas, Amany Farag & Ashley Shepherd. (2017) Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. BMC Gastroenterology 17:1.
Crossref
Crossref
Shereen Abdel Alem, Aisha Elsharkawy, Rabab Fouad, Eman Adel, Zeinab Abdellatif, Sherief Musa, Ahmed Nagy, Muhammad S. Hussein, Ayman Yosry & Gamal Esmat. (2017) Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. Journal of Medical Virology 89:12, pages 2181-2187.
Crossref
Crossref
Jacqueline Farinha Shimizu, Caroline Sprengel Lima, Carina Machado Pereira, Cintia Bittar, Mariana Nogueira Batista, Ana Carolina Nazaré, Carlos Roberto Polaquini, Carsten Zothner, Mark Harris, Paula Rahal, Luis Octávio Regasini & Ana Carolina Gomes Jardim. (2017) Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry. Scientific Reports 7:1.
Crossref
Crossref
Aisha Elsharkawy, Shereen Abdel Alem, Rabab Fouad, Maissa El Raziky, Wafaa El Akel, Mahmoud Abdo, Omnia Tantawi, Mohamed AbdAllah, Marc Bourliere & Gamal Esmat. (2017) Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. Journal of Gastroenterology and Hepatology 32:9, pages 1624-1630.
Crossref
Crossref
Rasha Eletreby, Wafaa Elakel, Mohamed Said, Mohamed El Kassas, Sameh Seif, Tamer Elbaz, Maissa El Raziky, Siham Abdel Rehim, Samy Zaky, Rabab Fouad, Hadeel Gamal Eldeen, Mahmoud Abdo, Mohamed Korany, Ayman Yosry, Magdy El Serafy, Manal Hamdy El-Sayed, Yehia ElShazly, Imam Waked, Wahid Doss & Gamal Esmat. (2017) Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver International 37:4, pages 534-541.
Crossref
Crossref
A. Elsharkawy, R. Fouad, W. El Akel, M. El Raziky, M. Hassany, G. Shiha, M. Said, I. Motawea, T. El Demerdash, S. Seif, A. Gaballah, Y. El Shazly, M. A. M. Makhlouf, I. Waked, A. O. Abdelaziz, A. Yosry, M. El Serafy, M. Thursz, W. Doss & G. Esmat. (2017) Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Alimentary Pharmacology & Therapeutics 45:5, pages 681-687.
Crossref
Crossref
Michael J. Sofia. 2016. Successful Drug Discovery. Successful Drug Discovery
163
188
.
L. Benítez-Gutiérrez, C. de Mendoza, I. Baños, A. Duca, A. Arias, A. Treviño, S. Requena, M.J. Citores & V. Cuervas-Mons. (2016) Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. Transplantation Proceedings 48:7, pages 2515-2518.
Crossref
Crossref
Andrea Magri, Alexander A. Ozerov, Vera L. Tunitskaya, Vladimir T. Valuev-Elliston, Ahmed Wahid, Mario Pirisi, Peter Simmonds, Alexander V. Ivanov, Mikhail S. Novikov & Arvind H. Patel. (2016) Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Scientific Reports 6:1.
Crossref
Crossref
Ayman Yosry, Rabab Fouad, Shereen A. Alem, Aisha Elsharkawy, Mohammad El-Sayed, Noha Asem, Ehsan Hassan, Ahmed Ismail & Gamal Esmat. (2016) FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology 17:2, pages 78-83.
Crossref
Crossref
Courtney M. Boucher, Anne Walsh & Christopher P. Forest. (2016) Healing livers, saving lives. Journal of the American Academy of Physician Assistants 29:5, pages 20-28.
Crossref
Crossref
D. Banerjee & K. R. Reddy. (2016) Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 43:6, pages 674-696.
Crossref
Crossref
Mandeep R. Mehra, Charles E. Canter, Margaret M. Hannan, Marc J. Semigran, Patricia A. Uber, David A. Baran, Lara Danziger-Isakov, James K. Kirklin, Richard Kirk, Sudhir S. Kushwaha, Lars H. Lund, Luciano Potena, Heather J. Ross, David O. Taylor, Erik A.M. Verschuuren & Andreas Zuckermann. (2016) The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. The Journal of Heart and Lung Transplantation 35:1, pages 1-23.
Crossref
Crossref
Maigeng Zhou, Haidong Wang, Jun Zhu, Wanqing Chen, Linhong Wang, Shiwei Liu, Yichong Li, Lijun Wang, Yunning Liu, Peng Yin, Jiangmei Liu, Shicheng Yu, Feng Tan, Ryan M Barber, Matthew M Coates, Daniel Dicker, Maya Fraser, Diego González-Medina, Hannah Hamavid, Yuantao Hao, Guoqing Hu, Guohong Jiang, Haidong Kan, Alan D Lopez, Michael R Phillips, Jun She, Theo Vos, Xia Wan, Gelin Xu, Lijing L Yan, Chuanhua Yu, Yong Zhao, Yingfeng Zheng, Xiaonong Zou, Mohsen Naghavi, Yu Wang, Christopher J L Murray, Gonghuan Yang & Xiaofeng Liang. (2016) Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. The Lancet 387:10015, pages 251-272.
Crossref
Crossref
Richard A. Helmers, Thomas J. Byrne, Lewis J. Wesselius & Kevin O. Leslie. (2015) Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient. Mayo Clinic Proceedings 90:9, pages 1294-1297.
Crossref
Crossref
Erik De Clercq. (2015) Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. Reviews in Medical Virology 25:4, pages 254-267.
Crossref
Crossref
Paul Y. Kwo & Maaz B. Badshah. (2015) New hepatitis C virus therapies. Current Opinion in Organ Transplantation 20:3, pages 235-241.
Crossref
Crossref
Tamer Elbaz, Mohamed El-Kassas & Gamal Esmat. (2015) New era for management of chronic hepatitis C virus using direct antiviral agents: A review. Journal of Advanced Research 6:3, pages 301-310.
Crossref
Crossref
Tawhida Y Abdel-Ghaffar. (2015) Hepatitis C genotype 4: The past, present, and future. World Journal of Hepatology 7:28, pages 2792.
Crossref
Crossref
Vasilios Papastergiou. (2015) Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World Journal of Clinical Cases 3:3, pages 210.
Crossref
Crossref
E. Riva, C. Scagnolari, O. Turriziani & G. Antonelli. (2014) Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment. Clinical Microbiology and Infection 20:12, pages 1237-1245.
Crossref
Crossref
Eleonora Grassi, Alessio Aghemo & Massimo Colombo. (2014) Optimal Management of Hepatitis C Genotype 2 Chronic Infection. Current Hepatology Reports 13:4, pages 273-278.
Crossref
Crossref
Rebecca L. Morgan. (2014) How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C. Journal of Gastroenterology 49:11, pages 1514-1515.
Crossref
Crossref